ACRS – Aclaris Therapeutics Inc
ACRS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
11.72
Margin Of Safety %
Put/Call OI Ratio
0.48
EPS Next Q Diff
-1.04
EPS Last/This Y
-0.12
EPS This/Next Y
-0.17
Price
5.91
Target Price
10.64
Analyst Recom
1.17
Performance Q
21.6
Upside
-229.8%
Beta
0.8
Ticker: ACRS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ACRS | 5.49 | 0.35 | 0.86 | 10848 |
| 2026-07-14 | ACRS | 5.42 | 0.35 | 0.50 | 10894 |
| 2026-07-15 | ACRS | 5.61 | 0.35 | 999.99 | 10903 |
| 2026-07-16 | ACRS | 5.37 | 0.35 | 0.58 | 10913 |
| 2026-07-17 | ACRS | 5.68 | 0.35 | 0.01 | 10977 |
| 2026-07-20 | ACRS | 5.57 | 0.36 | 0.42 | 10617 |
| 2026-07-21 | ACRS | 5.68 | 0.36 | 0.63 | 10683 |
| 2026-07-22 | ACRS | 5.63 | 0.36 | 0.02 | 10750 |
| 2026-07-23 | ACRS | 5.47 | 0.36 | 2.14 | 10763 |
| 2026-07-24 | ACRS | 5.23 | 0.36 | 2.38 | 10780 |
| 2026-07-27 | ACRS | 5.36 | 0.36 | 1.45 | 10776 |
| 2026-07-28 | ACRS | 5.32 | 0.37 | 0.00 | 10884 |
| 2026-07-29 | ACRS | 5.12 | 0.37 | 10.43 | 10884 |
| 2026-07-30 | ACRS | 5.32 | 0.38 | 0.01 | 11004 |
| 2026-07-31 | ACRS | 5.2 | 0.38 | 0.00 | 11034 |
| 2026-08-03 | ACRS | 5.53 | 0.38 | 0.37 | 11034 |
| 2026-08-04 | ACRS | 5.98 | 0.38 | 0.91 | 11099 |
| 2026-08-05 | ACRS | 6.34 | 0.44 | 0.22 | 12755 |
| 2026-08-07 | ACRS | 5.91 | 0.48 | 1.72 | 13260 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ACRS | 5.49 | -23.1 | - | -0.66 |
| 2026-07-14 | ACRS | 5.42 | -23.1 | - | -0.66 |
| 2026-07-15 | ACRS | 5.61 | -23.1 | - | -0.66 |
| 2026-07-16 | ACRS | 5.37 | -23.1 | - | -0.66 |
| 2026-07-17 | ACRS | 5.67 | -23.1 | - | -0.66 |
| 2026-07-20 | ACRS | 5.57 | -23.1 | - | -0.66 |
| 2026-07-21 | ACRS | 5.69 | -23.1 | - | -0.66 |
| 2026-07-22 | ACRS | 5.62 | -23.1 | - | -0.66 |
| 2026-07-23 | ACRS | 5.48 | -23.1 | - | -0.66 |
| 2026-07-24 | ACRS | 5.23 | -23.1 | - | -0.66 |
| 2026-07-27 | ACRS | 5.36 | -23.1 | - | -0.66 |
| 2026-07-28 | ACRS | 5.32 | -23.1 | - | -0.66 |
| 2026-07-29 | ACRS | 5.12 | -23.1 | - | -0.66 |
| 2026-07-30 | ACRS | 5.31 | -23.1 | - | -0.66 |
| 2026-07-31 | ACRS | 5.20 | -23.1 | - | -0.66 |
| 2026-08-03 | ACRS | 5.52 | -23.1 | - | -0.66 |
| 2026-08-04 | ACRS | 5.52 | -23.1 | - | -0.66 |
| 2026-08-05 | ACRS | 6.35 | -23.1 | - | -0.66 |
| 2026-08-06 | ACRS | 6.09 | -23.1 | - | -0.66 |
| 2026-08-07 | ACRS | 5.91 | -23.1 | - | -0.66 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ACRS | -1.16 | 13.24 | 10.00 |
| 2026-07-14 | ACRS | -1.16 | 13.24 | 10.00 |
| 2026-07-15 | ACRS | -1.16 | 13.24 | 10.00 |
| 2026-07-16 | ACRS | -1.16 | 13.24 | 10.00 |
| 2026-07-17 | ACRS | -1.16 | 13.24 | 10.00 |
| 2026-07-20 | ACRS | -1.16 | 13.28 | 10.00 |
| 2026-07-21 | ACRS | -1.16 | 13.28 | 10.00 |
| 2026-07-22 | ACRS | -1.16 | 13.28 | 10.00 |
| 2026-07-23 | ACRS | -1.16 | 13.28 | 10.00 |
| 2026-07-24 | ACRS | -1.16 | 13.28 | 10.00 |
| 2026-07-27 | ACRS | -1.16 | 13.26 | 11.72 |
| 2026-07-28 | ACRS | -1.16 | 13.26 | 11.72 |
| 2026-07-29 | ACRS | -1.16 | 13.26 | 11.72 |
| 2026-07-30 | ACRS | -1.16 | 13.26 | 11.72 |
| 2026-07-31 | ACRS | -1.16 | 13.26 | 11.72 |
| 2026-08-03 | ACRS | -1.16 | 13.35 | 11.72 |
| 2026-08-04 | ACRS | -1.16 | 13.35 | 11.72 |
| 2026-08-05 | ACRS | -1.16 | 13.35 | 11.72 |
| 2026-08-06 | ACRS | -1.16 | 13.35 | 11.72 |
| 2026-08-07 | ACRS | -1.16 | 13.35 | 11.72 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.87
Avg. EPS Est. Current Quarter
-0.16
Avg. EPS Est. Next Quarter
-0.17
Insider Transactions
-1.16
Institutional Transactions
13.35
Beta
0.8
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
26
Growth Score
23
Sentiment Score
99
Actual DrawDown %
70.4
Max Drawdown 5-Year %
-96.6
Target Price
10.64
P/E
Forward P/E
PEG
P/S
100.41
P/B
6.63
P/Free Cash Flow
EPS
-0.59
Average EPS Est. Cur. Y
-0.66
EPS Next Y. (Est.)
-0.83
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-921.5
Relative Volume
1.34
Return on Equity vs Sector %
-75.8
Return on Equity vs Industry %
-59.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
ACRS
Healthcare
$5.91
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
58.1
Range 1M
57.5%
Sup Dist
1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-24.7%
EPS NY
-16.8%
52W%
87.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+80% upside
Upside
+80%
Quality
26
ACRS — P/E HistoricalBiotechnology
Aclaris Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 69
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS
Latest News
—
Caricamento notizie per ACRS…
stock quote shares ACRS – Aclaris Therapeutics Inc Stock Price stock today
news today ACRS – Aclaris Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ACRS – Aclaris Therapeutics Inc yahoo finance google finance
stock history ACRS – Aclaris Therapeutics Inc invest stock market
stock prices ACRS premarket after hours
ticker ACRS fair value insiders trading